NorthWest Biotherapeutics Inc (NWBO)

[FeMike]

This is a fair argument and in thinking on this, I suppose there is a lobby of interested parties completely unrelated to the stock market that could influence early opinion on partial data negatively with regulatory agencies. Probably the only argument I’d entertain.

However, I still don’t believe that releasing TLD now would impact approval barring a complete failure, which we obviously don’t have. The journal should clear any fog that is created from TLD being not a 360 degree look at the trial. Especially if approval processes have already been underway in the background.